Valeant's CEO apologized, but the rest of the industry is still hiking drug prices

Thomson Reuters The outgoing CEO of embattled Valeant Pharmaceutical delivered a mea culpa to members of Congress on Wednesday morning, saying that he and his company had been “too aggressive” in acquiring drugs and shamelessly jacking up their prices at the expense of consumers, insurers and government health care agencies. “Let me state plainly that it was a mistake to pursue, and in hindsight I regret pursuing, transactions where a central premise was a planned increase in the prices of...